Boston puts brave face on cardiac meltdown
This article was originally published in Clinica
Executive Summary
Boston Scientific, beset with uncertainty over its attempt to buy out Medinol and still recovering from two years of accounting irregularities, product recalls, adverse incidents and a lost legal battle with Johnson & Johnson, has reported dramatically slumping sales for last year. The damage, which accelerated in the fourth quarter, is located in its Scimed cardiology division.